《心脏装置患者的MRI安全性》

  • 来源专题:心血管疾病防治
  • 编译者: 张燕舞
  • 发布时间:2018-05-22
  • 永久性起搏器或植入式心脏复律除颤器(ICD)患者的磁共振成像(MRI)潜在风险包括编程改变,起搏异常和导线中的感应电流。在一系列1509名患有老一代起搏器或ICD的患者(例如,那些不特别符合食品和药物管理局规定的MRI-条件标准或“传统”设备的患者)中进行胸部或非胸部MRI检查以及随访1年,没有临床意义的事件。虽然这个和以前的报道令人放心,但是在MRI和成像过程中的患者监护之前和之后,可以使用除颤器和代码手推车,非MRI有条件的起搏器或ICD需要采取预防措施,包括设备编程。如果检查对于疾病的诊断或治疗是必要的和必要的,那么在非MRI有条件的永久起搏器或ICD的患者中可以进行MR成像,只要采取了特定的预防措施。

    BACKGROUND Patients who have pacemakers or defibrillators are often denied the opportunity to undergo magnetic resonance imaging (MRI) because of safety concerns, unless the devices meet certain criteria specified by the Food and Drug Administration (termed "MRI-conditional" devices).

    METHODS We performed a prospective, nonrandomized study to assess the safety of MRI at a magnetic field strength of 1.5 Tesla in 1509 patients who had a pacemaker (58%) or an implantable cardioverter-defibrillator (42%) that was not considered to be MRI-conditional (termed a "legacy" device). Overall, the patients underwent 2103 thoracic and nonthoracic MRI examinations that were deemed to be clinically necessary. The pacing mode was changed to asynchronous mode for pacing-dependent patients and to demand mode for other patients. Tachyarrhythmia functions were disabled. Outcome assessments included adverse events and changes in the variables that indicate lead and generator function and interaction with surrounding tissue (device parameters).

    RESULTS No long-term clinically significant adverse events were reported. In nine MRI examinations (0.4%; 95% confidence interval, 0.2 to 0.7), the patient's device reset to a backup mode. The reset was transient in eight of the nine examinations. In one case, a pacemaker with less than 1 month left of battery life reset to ventricular inhibited pacing and could not be reprogrammed; the device was subsequently replaced. The most common notable change in device parameters (>50% change from baseline) immediately after MRI was a decrease in P-wave amplitude, which occurred in 1% of the patients. At long-term follow-up (results of which were available for 63% of the patients), the most common notable changes from baseline were decreases in P-wave amplitude (in 4% of the patients), increases in atrial capture threshold (4%), increases in right ventricular capture threshold (4%), and increases in left ventricular capture threshold (3%). The observed changes in lead parameters were not clinically significant and did not require device revision or reprogramming.

    CONCLUSIONS We evaluated the safety of MRI, performed with the use of a prespecified safety protocol, in 1509 patients who had a legacy pacemaker or a legacy implantable cardioverter-defibrillator system. No long-term clinically significant adverse events were reported. (Funded by Johns Hopkins University and the National Institutes of Health; ClinicalTrials.gov number, NCT01130896 .).

相关报告
  • 《体外连续性血流心室辅助装置(BR16010)的安全性和有效性研究》

    • 来源专题:重大疾病防治
    • 编译者:张燕舞
    • 发布时间:2019-07-15
    • 日本国立心脑血管疾病中心设计了一项单中心、单臂、开放标签、探索性临床研究,以探究一款装载一次性流体动力悬浮轴承离心泵的体外心室辅助装置用于重度心衰/难治性心源性休克患者过渡治疗的安全性和有效性。该研究预计共纳入9例患者,主要复合终点是患者存活且无器械相关的不良事件和并发症。左心室辅助成功标准为试验装置植入30天内心功能恢复并成功脱机,或转为其他心室辅助装置作为移植前的过渡治疗;右心辅助的成功标准是试验装置植入30天内心功能恢复至成功撤机。研究次要终点包括心室机械辅助总时长,以及植入后7天和脱机当天BNP水平、左心室射血分数和左心室舒张功能的变化。
  • 《推迟LVAD患者进入心脏移植候选名单的副作用》

    • 来源专题:重大疾病防治
    • 编译者:张燕舞
    • 发布时间:2019-07-15
    • 在植入左心室机械辅助(LVAD)进行辅助后,患者进入心脏移植候选名单的时机往往不能确定,不同中心存在不同的标准。这是由于部分患者存在较高的装置相关并发症发生率,而另一部分患者则比较稳定。该研究利用一种名为Markov的统计模型,模拟推迟进入心脏移植候选名单对LVAD辅助患者的死亡率和并发症发生率的影响。建模参数来源于标准移植分析和研究数据,主要分析5年结果。结果显示,推迟180天模型中的患者接受心脏移植的比例比基线模型中的患者要低(51% vs 53%);在等待接受移植期间,其死亡率增加(21% vs 17%)。当推迟180天进入名单后,患者的预期寿命略有下降(3.50年vs 3.51年)。结果表明,LVAD辅助患者在推迟进入移植候选名单后,其死亡风险增加,最终接受心脏移植的可能性下降,然而其预期寿命未受影响。在目前LVAD的技术水平下,通过推迟心脏移植以达到延长预期寿命的期望是不现实的。